Table 4.
Biological Activities of Nonpurified and Purified IFN-α Subtypes
| suIFN-α3 | IFN-α3 | suIFN-α4 | IFN-α4 | suIFN-α9 | IFN-α9 | |
|---|---|---|---|---|---|---|
| Antiviral activity (%)a | 28.0 | 13.7 | 52.6 | 7.4 | 5.1 | 6.5 |
| Anti-inflammatory activity (%)b | 128.8 | 100.0 | 121.2 | 119.4 | 86.1 | 113.0 |
| HLA class I expression (%)c | 70.6 | 51.8 | 80.9 | 75.8 | 62.94 | 62.4 |
| SLA class I expression (%)d | 51.5 | Neg | 45.4 | Neg | 43.37 | Neg |
| SLA class II expression (%)c | 54.1 | 50.9 | 57.3 | 44.3 | 57.47 | 46.6 |
a
Results are expressed as mean percentage of PRV copies with respect to the copy number measured in the untreated control sample (PRV-infected cells without any IFN-α subtype).
b
Results are expressed as mean percentage of IL-8 concentration (pg/mL) with respect to the level obtained in untreated control IPEC-J2 cells.
c
Results are expressed as mean percentage of positive cell fluorescence intensity values higher than the median of mock-treated control cells.
d
Results are expressed as mean percentage of SLA class I-positive cells.
PRV, pseudorabies virus.